Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?

Transl Lung Cancer Res. 2016 Oct;5(5):538-542. doi: 10.21037/tlcr.2016.10.01.

Authors

Wolfram C M Dempke¹, Klaus Fenchel²

Affiliations

¹ Department of Medical Oncology, Kyowa Kirin Pharmaceutical Development Ltd., Galashiels, UK;; Department of Haematology and Oncology, University Hospital of Grosshadern, University of Munich, Munich, Germany.
² Department of Medical, Medical School Hamburg (MSH), Hamburg, Germany.

No abstract available

Publication types

Editorial